The global demand for Oncology Drugs Market is presumed to reach the valuation of nearly USD XX MN by 2027 from USD XX MN in 2020 with a CAGR of XX% under the study period of 2021 - 2027. Whereas with regards to volume, the market was calculated XX Kilo Tons in 2020 and foreseen to touch XX Kilo Tons by 2027 with a CAGR of XX% during 2021-2027.
Oncology drugs refer to medications used for cancer treatment. A drug used in cancer treatment varies in structure and mechanism of action. It kills cancer cells, stops them from growing and spreading to other parts of the body, helps the body regain strength, and develop new healthy cells. It also treats symptoms that cancer causes, like pain. With advances in understanding cancer biology, better treatment options, including drugs, are being devised, leading to new products approval and launch.
The growing burden of cancer diseases drives the growth of the global oncology drugs market. According to the World Health Organization estimates, the worldwide cancer burden is assessed to have ascended to 18.1 million new cases, and 9.6 million passings in 2018. It is projected that by 2030 between 10 and 11 million cancers will be diagnosed each year in low- and middle-income countries. The expanding disease burden is because of a few elements, including the aging population, changing lifestyle, among others. The growing approval for new drugs by the FDA and rising penetration of health insurance is amplifying revenue growth. Malignant of the lung, female breast, and colorectum are the top three cancers in terms of incidence, estimated to hold the majority share in global terms. However, expensive treatment and limited treatment options restrain the growth of the market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of oncology drugs.
The entire oncology drugs market has been sub-categorized into drug class type and indication. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Drug Class Type
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancers
This section covers regional segmentation which accentuates on current and future demand for oncology drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Oncology Drugs Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the oncology drugs market include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, f. Hoffmann-La Roche ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co., Inc., Novartis AG, Pfizer Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.